

## AMENDMENTS TO THE CLAIMS

The claims in this listing will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

Claims 1 (Currently Amended): Sustained release tablet containing ~~indapamide, characterized in that the tablet contains indapamide in the amount~~ 1.5 to 2.5 % of the total mass of the tablet of indapamide, ~~lactose monohydrate in the amount 30 to 80 % of the total mass of the tablet~~ of lactose monohydrate, ~~copovidon in the amount of 2 to 10 % of the total mass of the tablet~~ of copovidon, ~~hypromellose in the amount of 20 to 65 % of the total mass of the tablet~~ of hypromellose, and ~~lubricants in the amount of 0.1 to 5 % of the total mass of the tablet~~ of lubricant.

Claim 2 (Currently Amended): ~~Tablet~~ The tablet according to claim 1, ~~characterized in that as the lubricants it contains~~ wherein said lubricant comprises at least one of magnesium stearate ~~or/and~~ and anhydrous colloidal silica.

Claim 3 (Currently Amended): ~~Tablet~~ The tablet according to claim 1, ~~characterized in that~~ wherein the hypromellose has a viscosity is from ~~1.000~~ 1,000 to ~~20.000~~ 20,000 cP.

Claim 4 (Currently Amended): Process of manufacturing sustained release tablet containing indapamide, ~~characterized in that~~ comprising mixing indapamide ~~is mixed~~ with lactose monohydrate and copovidone and then moisturizing the mixture ~~is moisturised by~~ with purified water and ~~its~~ performing granulation ~~is performed~~ after which the granulate is dried, cooled, mixed with hypromellose and ~~lubricants~~ lubricant and compressed in tableting machine.

Claim 5 (New): The process according to claim 4, wherein said lubricant comprises at least one of magnesium stearate and anhydrous colloidal silica.

Claim 6 (New): The process according to claim 4, wherein the hypromellose has a viscosity ~~is~~ from 1,000 to 20,000 cP.